Literature DB >> 3399052

Innervation of human hippocampus by noradrenergic systems: normal anatomy and structural abnormalities in aging and in Alzheimer's disease.

R E Powers1, R G Struble, M F Casanova, D T O'Connor, C A Kitt, D L Price.   

Abstract

Immunocytochemical studies, using an antibody directed against human dopamine beta-hydroxylase, identified an extensive plexus of noradrenergic axons/terminals in normal human hippocampus. In hippocampi of individuals with Alzheimer's disease, the density of noradrenergic innervation was reduced and abnormal noradrenergic axons, which exhibited multifocal enlargements, were present in the neuropil. Some of these neurites were clustered around deposits of amyloid (senile plaques), and these abnormalities were most common in CA3-4, a region normally showing a relatively high density of noradrenergic terminals. This investigation provides direct evidence for structural abnormalities of noradrenergic axons/nerve terminals in hippocampi of individuals with Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3399052     DOI: 10.1016/0306-4522(88)90248-5

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  10 in total

1.  Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport.

Authors:  E H Koo; S S Sisodia; D R Archer; L J Martin; A Weidemann; K Beyreuther; P Fischer; C L Masters; D L Price
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

Review 2.  Sleep disturbances in Alzheimer's and Parkinson's diseases.

Authors:  Sarah M Rothman; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2012-05-03       Impact factor: 3.843

3.  Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques.

Authors:  C Joachim; D Games; J Morris; P Ward; D Frenkel; D Selkoe
Journal:  Am J Pathol       Date:  1991-02       Impact factor: 4.307

4.  Stress rapidly increases alpha 1d adrenergic receptor mRNA in the rat dentate gyrus.

Authors:  Serge Campeau; Tara J Nyhuis; Elisabeth M Kryskow; Cher V Masini; Jessica A Babb; Sarah K Sasse; Benjamin N Greenwood; Monika Fleshner; Heidi E W Day
Journal:  Brain Res       Date:  2010-02-06       Impact factor: 3.252

5.  Regulation of hippocampal alpha1d adrenergic receptor mRNA by corticosterone in adrenalectomized rats.

Authors:  Heidi E W Day; Elisa M Kryskow; Stanley J Watson; Huda Akil; Serge Campeau
Journal:  Brain Res       Date:  2008-05-01       Impact factor: 3.252

6.  Hypothyroidism-evoked shifts in hippocampal adrenergic receptors: implications to ischemia-induced hippocampal damage.

Authors:  S J Hemmings; A Shuaib
Journal:  Mol Cell Biochem       Date:  1998-08       Impact factor: 3.396

7.  Quantitative receptor autoradiography of eight different transmitter-binding sites in the hippocampus of the common marmoset, Callithrix jacchus.

Authors:  M Kraemer; K Zilles; A Schleicher; R Gebhard; T W Robbins; B J Everitt; I Divac
Journal:  Anat Embryol (Berl)       Date:  1995-03

8.  An experimental model of Braak's pretangle proposal for the origin of Alzheimer's disease: the role of locus coeruleus in early symptom development.

Authors:  Abhinaba Ghosh; Sarah E Torraville; Bandhan Mukherjee; Susan G Walling; Gerard M Martin; Carolyn W Harley; Qi Yuan
Journal:  Alzheimers Res Ther       Date:  2019-07-03       Impact factor: 6.982

9.  Investigation of plasma metabolomics and neurotransmitter dysfunction in the process of Alzheimer's disease rat induced by amyloid beta 25-35.

Authors:  Mengying Wei; Yuanyuan Liu; Zifeng Pi; Kexin Yue; Shizhe Li; Mingxin Hu; Zhiqiang Liu; Fengrui Song; Zhongying Liu
Journal:  RSC Adv       Date:  2019-06-10       Impact factor: 4.036

10.  Three-dimensional synaptic organization of the human hippocampal CA1 field.

Authors:  Marta Montero-Crespo; Marta Dominguez-Alvaro; Patricia Rondon-Carrillo; Lidia Alonso-Nanclares; Javier DeFelipe; Lidia Blazquez-Llorca
Journal:  Elife       Date:  2020-07-21       Impact factor: 8.140

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.